GovChime
Notice ID: 20bc8e27870c483b89389f5392ddcd68SolicitationArchived

Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3

Archived on August 28, 2026. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
9:00 AM EDT
Posted
July 2, 2026
Notice type
Solicitation
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Department of WarDEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)

Notice details

Office
DEF ADVANCED RESEARCH PROJECTS AGCY
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
DARPA-PA-26-09
Notice ID
20bc8e27870c483b89389f5392ddcd68

Description

Please note that this announcement specifically solicits proposals only for Task Area 3 (TA-3) of the RAPIID program.

Primary challenges with translating technological advancements from the laboratory to real-world usage include a lack of investment to ensure manufacturing scalability, and usability, as well as clinical, regulatory, and commercialization preparedness. Previous investments by DARPA to address potential blood shortages in austere, pre-hospital settings (i.e., the Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP) program) have derisked scalable, shelf-stable components that would provide the resuscitative functions of whole blood (i.e., oxygen delivery, hemostasis, and volume expansion) when used together. However, bringing those components through clinical studies and regulatory approval as well as the development of enabling technologies and guidance to facilitate their use outside of the laboratory were out-of-scope in previous DARPA efforts. RAPIID is designed to bridge the gap between the proof-of-concept achievements of the FSHARP program and actual clinical use by the military and civilians. With FSHARP demonstrating that shelf-stable blood products can be created, DARPA is now taking on the next challenge: delivering a complete, deployable, and authorized system that can save lives in the field. To achieve this goal, RAPIID will focus on pushing high technology readiness level (TRL)/medical readiness level (MRL) capabilities through the regulatory process by funding studies to demonstrate safety and efficacy of blood analog components and their ability to work in combination; manufacturing scalability of individual blood analog components; and developing and scaling associated fielding technologies.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

LCDR Robert Murray, Program Manager, DARPA/BTO

Documents

Files (8)

  • DARPA-PA-26-09.pdf

    1.5 MBAdded in Solicitation version 3Posted
    Download
  • RAPIID_TA3_Attachment_F_Schedule_of_Milestones_and_Payments.xlsx

    25 KBAdded in Solicitation version 3Posted
    Download
  • RAPIID_TA3_Attachment_E_Task_Description_Document.docx

    37 KBAdded in Solicitation version 3Posted
    Download
  • RAPIID_TA3_Attachment_D_Sample_OT_R_.docx

    152 KBAdded in Solicitation version 3Posted
    Download
  • RAPIID_TA3_Attachment_B_Cost_Proposal.docx

    58 KBAdded in Solicitation version 3Posted
    Download
  • RAPIID_TA3_Attachment_A_Technical_Management_Proposal.docx

    64 KBAdded in Solicitation version 3Posted
    Download
  • RAPIID_TA3_Attachment_G_RAPIID_CUI_Guide.pdf

    281 KBAdded in Solicitation version 3Posted
    Download
  • RAPIID_TA3_Attachment_C_DARPA_Standard_Cost_Proposal_Spreadsheet.xlsx

    364 KBAdded in Solicitation version 3Posted
    Download

Lifecycle

  1. 3
    Version 3SolicitationArchivedCurrent

    Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3

    Notice 20bc8e27870c483b89389f5392ddcd68 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

DARPA-PA-26-09

Archive Date

Aug 28, 2026

Office Address

ARLINGTON, VA, 222032114